Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review

Current Cardiology Reviews

Volumn 5, Issue 4, 2009, Pages 296-311

  Kasapis, Christos ^a   Gurm, Hitinder S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; Management; Peripheral arterial disease; Popliteal artery; Superficial femoral artery

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; NAFTIDROFURYL; NITINOL; PACLITAXEL; PENTOXIFYLLINE; PLACEBO; RAMIPRIL; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ALGORITHM; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHERECTOMY; ATHEROSCLEROSIS; BALLOON DILATATION; BLOOD PRESSURE MEASUREMENT; BRACHYTHERAPY; BYPASS SURGERY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG SAFETY; ENDARTERECTOMY; EXTERNAL BEAM RADIOTHERAPY; FEMORAL ARTERY; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; LIFESTYLE MODIFICATION; LIMB ISCHEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MATERIAL COATING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPLITEAL ARTERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROTEINURIA; PULSE WAVE; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; STROKE; SUPERFICIAL FEMORAL POPLITEAL ARTERIAL DISEASE; TREADMILL EXERCISE; VASCULAR PATENCY; WALKING;

EID: 70449625257     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309789317823     Document Type: Review

References (131)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-743
3. Pasternak RC, Criqui MH, Benjamin EJ, et al. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. Circulation 2004; 109: 2605-2612 (Pubitemid 38720564)
4. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324 (Pubitemid 33015522)
5. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172-1181 (Pubitemid 27013522)
6. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 1999; 159: 387-392 (Pubitemid 29091628)
7. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-75.
8. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392
9. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26: 3333-3341
10. Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg 2001; 33: 251-257; discussion 257-258
11. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
12. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 2004; 57: 294-300.
13. Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988; 17: 248-254
14. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996; 22: 391-398 (Pubitemid 26166930)
15. Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg 1996; 24: 258-265
16. Bascom PA, Johnston KW, Cobbold RS, Ojha M. Defining the limitations of measurements from Doppler spectral recordings. J Vasc Surg 1996; 24: 34-44; discussion 44-135
17. Johnston KW, Kassam M, Cobbold RS. Relationship between Doppler pulsatility index and direct femoral pressure measurements in the diagnosis of aortoiliac occlusive disease. Ultrasound Med Biol 1983; 9: 271-281
18. de Vries SO, Hunink MG, Polak JF. Summary receiver operating characteristic curves as a technique for meta-analysis of the diagnostic performance of duplex ultrasonography in peripheral arterial disease. Acad Radiol 1996; 3: 361-369
19. Fletcher JP, Kershaw LZ, Chan A, Lim J. Noninvasive imaging of the superficial femoral artery using ultrasound Duplex scanning. J Cardiovasc Surg (Torino) 1990; 31: 364-367 (Pubitemid 20334385)
20. Moneta GL, Yeager RA, Lee RW, Porter JM. Noninvasive localization of arterial occlusive disease: a comparison of segmental Doppler pressures and arterial duplex mapping. J Vasc Surg 1993; 17: 578-582
21. Whelan JF, Barry MH, Moir JD. Color flow Doppler ultrasonography: comparison with peripheral arteriography for the investigation of peripheral vascular disease. J Clin Ultrasound 1992; 20: 369-374
22. Catalano C, Fraioli F, Laghi A, et al. Infrarenal aortic and lowerextremity arterial disease: diagnostic performance of multi-detector row CT angiography. Radiology 2004; 231: 555-563 (Pubitemid 38552917)
23. Martin ML, Tay KH, Flak B, et al. Multidetector CT angiography of the aortoiliac system and lower extremities: a prospective comparison with digital subtraction angiography. AJR Am J Roentgenol 2003; 180: 1085-1091 (Pubitemid 36363055)
24. Ota H, Takase K, Igarashi K, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. AJR Am J Roentgenol 2004; 182: 201-209 (Pubitemid 38017743)
25. Ofer A, Nitecki SS, Linn S, et al. Multidetector CT angiography of peripheral vascular disease: a prospective comparison with intraarterial digital subtraction angiography. AJR Am J Roentgenol 2003; 180: 719-724 (Pubitemid 36237215)
26. Kock MC, Adriaensen ME, Pattynama PM, et al. DSA versus multi-detector row CT angiography in peripheral arterial disease: randomized controlled trial. Radiology 2005; 237: 727-737
27. Schernthaner R, Stadler A, Lomoschitz F, et al. Multidetector CT angiography in the assessment of peripheral arterial occlusive disease: accuracy in detecting the severity, number, and length of stenoses. Eur Radiol 2008, 18: 665-671
28. Ouwendijk R, de Vries M, Pattynama PM, et al. Imaging peripheral arterial disease: a randomized controlled trial comparing contrast-enhanced MR angiography and multi-detector row CT angiography. Radiology 2005; 236: 1094-1103 (Pubitemid 41170878)
29. Ouwendijk R, Kock MC, van Dijk LC, van Sambeek MR, Stijnen T, Hunink MG. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. Radiology 2006; 241: 603-608 (Pubitemid 44632909)
30. Baum RA, Rutter CM, Sunshine JH, et al. Multicenter trial to evaluate vascular magnetic resonance angiography of the lower extremity. American College of Radiology Rapid Technology Assessment Group. JAMA 1995; 274: 875-880
31. Nelemans PJ, Leiner T, de Vet HC, van Engelshoven JM. Peripheral arterial disease: meta-analysis of the diagnostic performance of MR angiography. Radiology 2000; 217: 105-114 (Pubitemid 33097585)
32. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR Am J Roentgenol 2000; 174: 171-179
33. Owen RS, Carpenter JP, Baum RA, Perloff LJ, Cope C. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. N Engl J Med 1992; 326: 1577-1581
34. Food and Drug Administration Public Health Advisory: gadolinium- containing contrast agents for magnetic resonance imaging (MRI): Omniscan OM, Magnevist, ProHance, and MultiHance. June 2006. Available at http://www.fda.gov/cder/drug/advisory/gadolinium-agents.htm. Accessed February 2008.
35. Balduf LM, Langsfeld M, Marek JM, Tullis MJ, Kasirajan K, Matteson B. Complication rates of diagnostic angiography performed by vascular surgeons. Vasc Endovascular Surg 2002; 36: 439-445. (Pubitemid 35448760)
36. Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology 1997; 203: 611-620 (Pubitemid 27227402)
37. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 1799-1806
38. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499 (Pubitemid 36159884)
39. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159: 337-345 (Pubitemid 29091621)
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853 (Pubitemid 28416718)
41. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
42. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653 (Pubitemid 41817713)
43. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431
44. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
45. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22. (Pubitemid 34756487)
46. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333-335 (Pubitemid 28099310)
47. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007: CD000123.
48. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239 (Pubitemid 38924592)
49. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572 (Pubitemid 37430158)
50. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-1776
51. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
52. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006; 144: 660-664 (Pubitemid 46780650)
53. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000: CD000990.
54. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975-980
55. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-3116
56. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005; 45: 1563-1569 (Pubitemid 40704486)
57. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006: CD005263.
58. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002; 347: 1941-1951
59. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
60. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-419
61. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339
62. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717
63. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2001: CD001999.
64. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227 (Pubitemid 47080386)
65. Dorffler-Melly J, Buller HR, Koopman MM, Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003: CD000536.
66. Dorffler-Melly J, Koopman MM, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005: CD002071.
67. Girolami B, Bernardi E, Prins MH, et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000; 19: 370-380 (Pubitemid 30232609)
68. Watson HR, Bergqvist D. Antithrombotic agents after peripheral transluminal angioplasty: a review of the studies, methods and evidence for their use. Eur J Vasc Endovasc Surg 2000; 19: 445-450 (Pubitemid 30333069)
69. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-1319 (Pubitemid 35449476)
70. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530
71. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996; 155: 1053-1059 (Pubitemid 26358727)
72. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994; 23 (Suppl 3): S48-52.
73. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-2058
74. Cooper LT, Jr., Hiatt WR, Creager MA, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 235-239 (Pubitemid 34256763)
75. Rajagopalan S, Mohler ER, 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938
76. Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111: 1556-1566
77. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153: 874-880 (Pubitemid 46628792)
78. Kinney TB, Rose SC. Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. AJR Am J Roentgenol 1996; 166: 277-284
79. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001; 221: 137-145 (Pubitemid 32880382)
80. Mwipatayi BP, Hockings A, Hofmann M, Garbowski M, Sieunarine K. Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: A meta-analysis. J Vasc Surg 2008; 47: 461-469 (Pubitemid 351172652)
81. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol 2001; 12: 923-933
82. Yacyshyn VJ, Thatipelli MR, Lennon RJ, et al. Predictors of failure of endovascular therapy for peripheral arterial disease. Angiology 2006; 57: 403-417 (Pubitemid 44449038)
83. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991; 83: I70-80.
84. Holm J, Arfvidsson B, Jivegard L, et al. Chronic lower limb ischaemia. A prospective randomised controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg 1991; 5: 517-522
85. Wolf GL, Wilson SE, Cross AP, Deupree RH, Stason WB. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Interv Radiol 1993; 4: 639-648
86. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. Report of a prospective randomized trial in a selected group of patients. J Vasc Surg 1989; 9: 1-9.
87. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366: 1925-1934.
88. de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 2002; 222: 25-36. (Pubitemid 34031460)
89. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995; 274: 165-171
90. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol 1997; 20: 420-425
91. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol 1999; 18: 251-255 (Pubitemid 30153799)
92. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003; 37: 487-494 (Pubitemid 36350887)
93. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12: 23-31.
94. US Food and Drug Administration. Center for Devices and Radiological Health. Intracoil self-expanding peripheral stent - P000033 (2001). Available at: http: //www.fda.gov/cdrh/pdf/p000033.html. Accessed on November 2007.
95. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001; 12: 935-942
96. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007; 116: 285-292 (Pubitemid 47196564)
97. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115: 2745-2749 (Pubitemid 46842791)
98. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-1888 (Pubitemid 43872689)
99. Greenberg D, Rosenfield K, Garcia LA, et al. In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial). J Vasc Interv Radiol 2004; 15: 1065-1069
100. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 2004; 232: 516-521
101. Hayerizadeh R, Zeller T, Krankenberg H, et al. Long-term outcome of superficial femoral artery stenting using nitinol stents compared with stainless steel stents. A multicenter study. Am J Cardiol 2003; 92 (suppl): S157.
102. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315 (Pubitemid 40094743)
103. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13: 701-710
104. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-699
105. Ahmadi R, Schillinger M, Maca T, Minar E. Femoropopliteal arteries: immediate and long-term results with a Dacron-covered stent-graft. Radiology 2002; 223: 345-350 (Pubitemid 34454309)
106. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology 2000; 217: 95-104. (Pubitemid 33097584)
107. Saxon RR, Coffman JM, Gooding JM, Natuzzi E, Ponec DJ. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol 2003; 14: 303-311 (Pubitemid 36314758)
108. Saxon RR, Coffman JM, Gooding JM, Ponec DJ. Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions. J Vasc Interv Radiol 2007; 18: 1341-49; quiz 1350.
109. Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J Vasc Surg 2007; 45: 10-16; discussion 16.
110. US Food and Drug Administration, Center for Devices and Radiological Health. Gore Viabahn Endoprosthesis - P040037 (2005). Available at: http: //www.fda.gov/cdrh/pdf4/p040037.html. Accessed on November 2007.
111. Vroegindeweij D, Tielbeek AV, Buth J, Schol FP, Hop WC, Landman GH. Directional atherectomy versus balloon angioplasty in segmental femoropopliteal artery disease: two-year follow-up with color-flow duplex scanning. J Vasc Surg 1995; 21: 255-268; discussion 268-1259
112. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol 2006; 48: 1573-1578.
113. Zeller T, Krankenberg H, Rastan A, et al. Percutaneous rotational and aspiration atherectomy in infrainguinal peripheral arterial occlusive disease: a multicenter pilot study. J Endovasc Ther 2007; 14: 357-364.
114. Scheinert D, Laird JR, Jr., Schroder M, Steinkamp H, Balzer JO, Biamino G. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther 2001; 8: 156-166. (Pubitemid 32423620)
115. Laird JR, Zeller T, Gray BH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther 2006; 13: 1-11. (Pubitemid 43273492)
116. Nelson PR, Powell RJ, Proia RR, et al. Results of endovascular superficial femoral endarterectomy. J Vasc Surg 2001; 34: 526-531.
117. Rosenthal D, Martin JD, Smeets L, et al. Remote superficial femoral artery endarterectomy and distal aSpire stenting: results of a multinational study at three-year follow-up. J Cardiovasc Surg (Torino) 2006; 47: 385-391. (Pubitemid 44463378)
118. US Food and Drug Administration, Center for Devices and Radiological Health. Class 1 Recall: Boston Scientific Flextome Cutting Balloon Systems. Available at: http://wwwfdagov/cdrh/recalls/ recall-120705html Accessed on February 2008.
119. Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol 2005; 16: 1067-1073. (Pubitemid 41177119)
120. Laird JR, Biamino G, McNamara T, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow-up results. J Endovasc Ther 2006; 13 Suppl 2: II52-59.
121. Diehm N, Silvestro A, Do DD, et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. J Endovasc Ther 2005; 12: 723-730. (Pubitemid 43100930)
122. Wolfram RM, Budinsky AC, Pokrajac B, Potter R, Minar E. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five-year follow-up--prospective randomized study. Radiology 2006; 240: 878-884. (Pubitemid 44267347)
123. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. Circulation 2000; 102: 2694-2699.
124. Wolfram RM, Budinsky AC, Pokrajac B, Potter R, Minar E. Vascular brachytherapy with 192Ir after femoropopliteal stent implantation in high-risk patients: twelve-month follow-up results from the Vienna-5 trial. Radiology 2005; 236: 343-351. (Pubitemid 40853333)
125. Bonvini R, Baumgartner I, Do DD, et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol 2003; 41: 409-412. (Pubitemid 36164494)
126. Therasse E, Donath D, Lesperance J, et al. External beam radiation to prevent restenosis after superficial femoral artery balloon angioplasty. Circulation 2005; 111: 3310-3315. (Pubitemid 40875005)
127. Zabakis P, Kardamakis DM, Siablis D, et al. External beam radiation therapy reduces the rate of re-stenosis in patients treated with femoral stenting: results of a randomised study. Radiother Oncol 2005; 74: 11-16. (Pubitemid 40430942)
128. Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg 2000; 31: 417-425. (Pubitemid 30158002)
129. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg 2000; 32: 268-277
130. Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg 2003; 37: 149-155 (Pubitemid 36236959)
131. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, Harrington DP. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis Making 1994; 14: 71-81. (Pubitemid 24032684)